TALECRIS VISION
CORPORATE SITES
Talecris Canada
Talecris Europe
Talecris United States
View All
PRODUCT SITES
Alpha-1 Antitrypsin Deficiency
(Prolastin/Prolastina)
Immune Globulin Intravenous
Therapy
(IGIV) (Gamunex)
Antihemophilic Factor VIII
(Koāte-DVI)
Antithrombin III (AT III)
(Thrombate)
Human Albumin Products
(Plasbumin / Plasmanate)
Hyperimmune Globulin Therapy
(Hypermunes)
View All
PROGRAMS & SERVICES
Gamunex Connexions
Gamunex Direct
Prolastin Direct
Contract Manufacturing Services
Talecris Plasma Resources
View All
CONTACT TALECRIS
Home
About Talecris
Therapeutic Areas
Research & Development
Donor to Patient
Business Development
Investor Relations
Media Center
Media Center Overview
Press Releases
Press Releases Archive
News Features
The History of Talecris
Talecris Leadership
Talecris Media Contact Information
Media Center Overview
Press Releases
Subscribe to the Talecris Press Release RSS feed (W3C validated, Requires IE7 or higher)
December 17, 2009
Dean Mitchell Appointed to Talecris Board of Directors
November 10, 2009
Talecris Biotherapeutics Announces Third Quarter 2009 Results
October 30, 2009
Talecris Biotherapeutics to Report Third Quarter 2009 Financial Results
October 21, 2009
Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
October 16, 2009
Talecris Biotherapeutics Announces Pricing of $600 Million Senior Notes due 2016
See how Talecris is being
recognized for innovation and commitment
.
Contact Talecris
Glossary
Site Map
General Conditions of Use
Privacy Statement
California Compliance
© 2009 Talecris Biotherapeutics
